The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ecog performance status of 3 and 4

Clinical Colorectal Cancer

Volumn 14, Issue 1, 2015, Pages 52-57

  Crosara Teixeira, Marcela ^a,b   Marques, Daniel Fernandes ^a,b   Ferrari, Anezka Celis ^a,b   Alves, Michel Fabiano Silva ^a   Alex, Alexandra Khichfy ^a   Sabbaga, Jorge ^a,b   Hoff, Paulo M ^a,b   Riechelmann, Rachel P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Best supportive care; Care; Chemotherapy; Colorectal cancer; Palliative; Poor performance status

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METASTATIC COLORECTAL CANCER; PREDICTIVE VALUE; UNSPECIFIED SIDE EFFECT; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG MONITORING; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84922620746     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.09.010     Document Type: Article

References (24)

1. P.C. Simmonds Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group BMJ 321 2000 531 535
2. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
3. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
4. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
5. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786
6. M.T. Seymour, T.S. Maughan, and J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152
7. D.J. Sargent, C.H. Kohne, and H.K. Sanoff Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer J Clin Oncol 27 2009 1948 1955
8. J.P. Kuebler, H.S. Wieand, and M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204
9. D.R. Nebuloni, M.P. Mak, and F.H. Souza Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in public health system in Brazil: effectiveness and cost-utility analysis Mol Clin Oncol 1 2013 175 179
10. K.M. Tveit, T. Guren, and B. Glimelius Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study J Clin Oncol 30 2012 1755 1762
11. H.K. Sanoff, D.J. Sargent, and M.E. Campbell Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 J Clin Oncol 26 2008 5721 5727
12. R.A. Adams, A.M. Meade, and M.T. Seymour Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet Oncol 12 2011 642 653
13. J.M. Weiss, P.R. Pfau, and E.S. O'Connor Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data J Clin Oncol 29 2011 4401 4409
14. R.A. Meguid, M.B. Slidell, C.L. Wolfgang, D.C. Chang, and N. Ahuja Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 15 2008 2388 2394
15. F. Benedix, R. Kube, F. Meyer, U. Schmidt, I. Gastinger, and H. Lippert Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival Dis Colon Rectum 53 2010 57 64
16. F. Benedix, F. Meyer, and R. Kube Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma Pathol Res Pract 208 2012 592 597
17. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
18. M. Ducreux, D. Malka, and J. Mendiboure Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial Lancet Oncol 12 2011 1032 1044
19. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer J Clin Oncol 16 1998 301 308
20. J. Feliu, M.J. Safont, and A. Salud Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Br J Cancer 102 2010 1468 1473
21. F.F. Kabbinavar, J. Hambleton, R.D. Mass, H.I. Hurwitz, E. Bergsland, and S. Sarkar Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
22. E. Vrdoljak, T. Omrcen, M. Boban, and A. Hrabar Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer Anticancer Drugs 22 2011 191 197
23. I. Lang, C.H. Kohne, and G. Folprecht Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin Eur J Cancer 49 2013 439 448
24. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342